"Retreatment" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
The therapy of the same disease in a patient, with the same agent or procedure repeated after initial treatment, or with an additional or alternate measure or follow-up. It does not include therapy which requires more than one administration of a therapeutic agent or regimen. Retreatment is often used with reference to a different modality when the original one was inadequate, harmful, or unsuccessful.
| Descriptor ID |
D019233
|
| MeSH Number(s) |
E02.887
|
| Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Retreatment".
Below are MeSH descriptors whose meaning is more specific than "Retreatment".
This graph shows the total number of publications written about "Retreatment" by people in this website by year, and whether "Retreatment" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2010 | 0 | 1 | 1 |
| 2011 | 0 | 2 | 2 |
| 2012 | 0 | 1 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Retreatment" by people in Profiles.
-
Flow Diverter Performance in Aneurysms Arising From the Posterior Communicating Artery: A Systematic Review and Meta-Analysis. Neurosurgery. 2023 10 01; 93(4):764-772.
-
Incidence and significance of injuries on secondary CT imaging after initial selective imaging in blunt trauma patients. Am J Emerg Med. 2020 08; 38(8):1588-1593.
-
Prospective study on embolization of intracranial aneurysms with the pipeline device: the PREMIER study 1 year results. J Neurointerv Surg. 2020 Jan; 12(1):62-66.
-
Increased Duration of Operating Time for Carotid Endarterectomy Is Associated with Increased Mortality. Ann Vasc Surg. 2016 Oct; 36:166-174.
-
Predicting early and sustained virological responses in prior nonresponders to pegylated interferon alpha-2b plus ribavirin retreated with peginterferon alpha-2a plus ribavirin and the benefit-risk ratio of retreatment. J Clin Gastroenterol. 2013 Oct; 47(9):786-93.
-
A phase I dose escalation study of Ad GV.EGR.TNF.11D (TNFerade? Biologic) with concurrent chemoradiotherapy in patients with recurrent head and neck cancer undergoing reirradiation. Ann Oncol. 2013 Mar; 24(3):769-76.
-
Prior chemoradiotherapy adversely impacts outcomes of recurrent and second primary head and neck cancer treated with concurrent chemotherapy and reirradiation. Cancer. 2011 Oct 15; 117(20):4671-8.
-
Repeat use of human recombinant bone morphogenetic protein-2 for second level lumbar arthrodesis. Spine (Phila Pa 1976). 2011 Feb 01; 36(3):192-6.
-
Efficacy and safety of clofarabine in relapsed and/or refractory non-Hodgkin lymphoma, including rituximab-refractory patients. Cancer. 2011 Apr 01; 117(7):1490-7.
-
Re-treatment of patients with chronic hepatitis C who do not respond to peginterferon-alpha2b: a randomized trial. Ann Intern Med. 2009 Apr 21; 150(8):528-40.